Neonatal opioid withdrawal syndrome (NOWS) is a growing public health concern. The
complexity of in utero opioid exposure in clinical studies makes it difficult to investigate …

Abstract Morphine‐6‐glucuronide (M6G) appears to show equivalent analgesia to morphine
but to have a superior side‐effect profile in terms of reduced liability to induce nausea and …

Glucuronidation is a major detoxification pathway for endogenous and exogenous
compounds in mammals that results in the intracellular formation of polar metabolites …

Transfer of knowledge along the different phases of drug development is a fundamental
process in pharmaceutical research. In particular, cross-species extrapolation between …

Opiates are potent analgesics but their clinical use is limited by side effects including
analgesic tolerance and opioid-induced hyperalgesia (OIH). The Opiates produce analgesia …

It has been demonstrated that opioid agonists that preferentially act at μ-opioid receptors to
activate G protein signaling over βarrestin2 recruitment produce antinociception with less …

Traditional methods for site-specific drug delivery in the brain are slow, invasive, and difficult
to interface with recordings of neural activity. Here, we demonstrate the feasibility and …

Withdrawal from chronic opiates is associated with an increase in anxiogenic-like
behaviours, but the anxiety profile in the morphine-dependent animals is not clear. Thus …

Morphine remains the gold standard painkiller available to date to relieve severe pain.
Morphine metabolism leads to the production of two predominant metabolites, morphine-3 …

Current therapies to treat skeletal fracture pain are extremely limited. Some non-steroidal
anti-inflammatory drugs have been shown to inhibit bone healing and opiates induce …